Build a biomarker case

Name a biomarker and attach a folder of publications, and Anara synthesizes its published performance, populations studied, comparison to the gold standard, and guideline endorsements, citing the paper behind every data point. Use it to map evidence gaps early in a program or to build the foundation for a regulatory or market access case.

Prompt

A clinical research scientist at a diagnostics company builds the case for a cardiac transplant biomarker from 23 publications.

I am building a clinical evidence case for donor-derived cell-free DNA (dd-cfDNA) as a non-invasive alternative to endomyocardial biopsy for detecting cardiac allograft vasculopathy and rejection. My publications are in the folder "dd-cfDNA Cardiac Evidence."

Across these papers, synthesize:
1. The published sensitivity and specificity range, with the studies at each end of the range
2. Which patient populations have been studied (transplant type, timing post-transplant, center characteristics)
3. How dd-cfDNA compares to endomyocardial biopsy as the reference standard, including concordance data
4. Which guidelines or professional societies have endorsed or reviewed dd-cfDNA in this indication
5. The outstanding clinical questions the literature has not answered

Use only papers in my folder. Cite the specific paper and passage for every data point. Flag any performance claim where fewer than three papers agree.

What to add to your library

• Required: a folder containing the publications you want synthesized.
• Optional: the regulatory or market access context you are building toward, such as EU MDR clinical evaluation, FDA 510(k), or HEOR submission.
• Optional: one or two anchor studies that every other paper should be compared against.

What you get

• A structured synthesis organized around the performance dimensions you named, with per-claim citations.
• A summary of outstanding clinical gaps in the published literature.
• Flags wherever fewer than three papers agree, so you see thin evidence before a reviewer does.

Follow-ups

Map the gaps for your next study design.

Based on the evidence synthesis, identify the three most significant gaps in the published literature that limit the clinical adoption case for dd-cfDNA. For each gap, describe what study design would most credibly address it.

Draft the evidence summary for a submission.

Write a 200-word clinical evidence summary for dd-cfDNA based on the synthesis. Use formal regulatory language suitable for a clinical evaluation report. Every claim must trace to the cited papers in the folder. Flag any claim where the evidence comes from fewer than two independent studies.

Tips

• Name the exact performance dimensions you need. Without them you get a general summary that may not match your submission structure.
• Keep the "fewer than three papers" flag. Single-study claims are a standard target for regulatory scrutiny.
• For regulatory submissions, pair the synthesis with the appraisal table workflow so every study gets a formal quality row.